The Technical Analyst
Taysha Gene Therapies, [TSHA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Taysha Gene Therapies, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
4.57% $2.41
America/New_York / 26 apr 2024 @ 15:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 449.78 mill |
| EPS: | -0.960 |
| P/E: | -2.51 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 187.02 mill |
| Avg Daily Volume: | 2.81 mill |
| RATING 2024-04-26 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.51 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.43x |
| Company: PE -2.51 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0745 (-103.10%) $-2.48 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.14 - 2.66 ( +/- 10.82%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-02 | Alam Kamran | Sell | 1 288 | Common Stock |
| 2024-01-02 | Alam Kamran | Buy | 590 413 | Common Stock |
| 2024-01-02 | Alam Kamran | Buy | 590 413 | Employee Stock Option (right to buy) |
| 2024-01-02 | Nagendran Sukumar | Buy | 863 617 | Common Stock |
| 2024-01-02 | Nagendran Sukumar | Buy | 863 617 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 95.35 |
| Last 97 transactions |
| Buy: 29 865 015 | Sell: 943 112 |
Forecast:
16:00 - $2.41
Live Trading Signals (every 1 min)
Forecast
1: 15:44 - $2.40
Forecast 2: 16:00 - $2.41
Forecast 3: 16:00 - $2.41
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.41 (4.57% ) |
| Volume | 0.719 mill |
| Avg. Vol. | 2.81 mill |
| % of Avg. Vol | 25.61 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TSHA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.575 | N/A | Active |
|---|
TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Latest Press Releases
2024-04-05 08:00:00 - Press Release
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dallas, april 05, 2024 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (cns), today announced that, on april 1, 2024, the compensation committee of taysha's board of directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the company's common stock in connection with their employment. the stock options were granted under the taysha gene therapies, inc. 2023 inducement plan as an inducement material to the individuals entering employment with taysha in accordance with nasdaq listing rule 5635(c)(4).
2024-03-19 16:01:00 - Press Release
Taysha Gene Therapies Reports Full Year 2023 Financial Results And Provides Corporate And Clinical Updates
Data from first adult patient in reveal phase 1/2 trial showed tsha-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent saes as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in rsbq at month six
2024-03-14 16:26:00 - Press Release
Taysha Gene Therapies To Release Full-year 2023 Financial Results, Provide Corporate And Clinical Updates And Host Conference Call On March 19
Dallas, march 14, 2024 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (taysha or the company), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (cns), today announced that it will report its financial results for the full-year ended december 31, 2023, provide corporate and clinical updates and host a corporate update conference call on tuesday, march 19, 2024, at 4:30 pm eastern time.
2024-03-01 17:08:00 - Press Release
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dallas, march 01, 2024 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (cns), today announced that, on march 1, 2024, the compensation committee of taysha's board of directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the company's common stock in connection with their employment. the stock options were granted under the taysha gene therapies, inc. 2023 inducement plan as an inducement material to the individuals entering employment with taysha in accordance with nasdaq listing rule 5635(c)(4).
2024-02-29 08:00:00 - Press Release
Taysha Gene Therapies Announces Updates To Tsha-102 Clinical Program In Rett Syndrome
Reveal adolescent and adult trial will proceed to high dose cohort following independent data monitoring committee approval of company's request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in q2 2024
Latest News
2024-03-19 21:04:06 - Seeking Alpha
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
2024-03-14 16:26:00 - GlobeNewsWire
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time.
2024-01-31 14:23:57 - InvestorPlace
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you're not going to get rich off of them.
2024-01-15 09:30:00 - The Motley Fool
3 Growth Stocks That Could Go Parabolic in 2024
Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.
2023-11-20 14:03:50 - PennyStocks
Which Penny Stocks Are Best? 3 That Insiders Like In November
The world of penny stocks is interesting, offering the promise of significant returns for those willing to dive into this niche market. There aren't any guarantees that you'll immediately hit it big as a trader.
2023-11-14 21:53:02 - Seeking Alpha
Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of Research and Development Kamran Alam - Chief Financial Officer Conference Call Participants Whitney Ijem - Canaccord Genuity Kristen Kluska - Cantor Fitzgerald Salveen Richter - Goldman Sachs Gil Blum - Needham & Co Yanan Zhu - Wells Fargo Securities Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - JMP Securities Operator Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
2023-11-03 19:41:25 - Seeking Alpha
Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting Rett Syndrome. The gene therapy market is projected to grow from $15.46 billion in 2022 to $82.24 billion by 2032, highlighting a shift towards personalized medicine. TSHA-102 has received the FDA's Fast Track Designation, expediting its Phase 1/2 trial with a roadmap to treat the first pediatric patient by Q1 2024.
2023-09-05 11:17:11 - Zacks Investment Research
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TSHA's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
2023-09-04 15:04:42 - InvestorPlace
3 Small-Cap Stocks to Sell in September Before They Crash & Burn
The market had a choppy August as traders digested the latest developments from a busy earnings season and a hawkish Federal Reserve. While the overall market is volatile, we've seen some large speculative run-ups amid small-cap stocks.
2023-05-11 23:13:02 - Seeking Alpha
Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan - CEO Sukumar Nagendran - President and Head of Research and Development Salman Bhai - Assistant Professor of Neurology at UT Kamran Alam - CFO Conference Call Participants Abigail Gray - Baird Gil Blum - Needham & Co. Operator Thank you for standing by. This is the conference operator.